Journal article
Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial
M Laman, BR Moore, JM Benjamin, G Yadi, C Bona, J Warrel, JH Kattenberg, T Koleala, L Manning, B Kasian, LJ Robinson, N Sambale, L Lorry, S Karl, WA Davis, A Rosanas-Urgell, I Mueller, PM Siba, I Betuela, TME Davis
Plos Medicine | Published : 2014
Abstract
Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are transmitted, especially in children, who bear the brunt of infection in endemic areas. In Papua New Guinea (PNG), artemether-lumefantrine is the first-line treatment for uncomplicated malaria, but it has limited efficacy against P. vivax. Artemisinin-naphthoquine should have greater activity in vivax malaria because the elimination of naphthoquine is slower than that of lumefantrine. In this study, the efficacy, tolerability, and safety of these ACTs were assessed in PNG children aged 0.5–5 y.An open-label, randomized, parallel-group trial of artemether-lumefantrine (six doses over 3..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
National Health and Medical Research Council (NHMRC https://www.nhmrc.gov.au/) grant #634343. Individual authors were supported by NHMRC funding: BRM by an Early Career Fellowship (#1036951), LJR an Early Career Fellowship (#1016443), IM a Senior Research Fellowship (#1043345), and TMED a Practitioner Fellowship (#572561). ML was supported by an Australian Award PhD Scholarship (http://education.gov.au/australian-postgraduate-awards), and TK was supported by an Esso-Highlands PNGIMR scholarship (http://www.pngimr.org.pg/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.